OncoBay signs on with physIQ’s latest clinical trial partner program

The Tampa, Florida-based research center, a subsidiary of the Moffit Cancer Center, will use physIQ’s Intrepid Partner Program to monitor and evaluate these patients and the effectiveness of treatments in near real-time through high-fidelity, medical-grade biosensor data streams.

PhysIQ debuted the program earlier this month with the goal of attracting CROs, academic research organizations and other tech companies with its portfolio of AI-based digital biomarkers, experience with government regulators and other technologies in clinical operations.

The program’s “predict-to-prevent” pharmacovigilance model was a big attraction for OncoBay, as it can provide...